Alvotech & Dr. Reddy's Partner on Keytruda Biosimilar

  Published 11 months ago

Alvotech and Dr. Reddy's are collaborating to develop, manufacture, and commercialize a biosimilar to Keytruda, a $29.5 billion cancer treatment. The partnership aims to accelerate development and expand global access.

  • Joint development and cost sharing.
  • Global commercialization rights for both.
  • Targets Keytruda’s $29.5B market.

You might like these

SBI Q1 Profit Boosted by Non-Interest Income

EMS Secures Two Major Water Projects in UP

Dhanlakshmi Bank Q1 FY26 Growth Report

KPI Green Jumps on Govt Approval

India's Copper Policy Attracts Foreign Smelters

L&T Bags Major Solar-BESS Order in Bihar

India Faces Slow Growth, Rate Cut Hopes

News that matters the most ⚡